Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.

Welty, Margaux; Mesana, Laura; Padhiar, Amie; Naessens, Dominik; Diels, Joris; van Sanden, Suzy; Pacou, Maud

Welty, Margaux; Mesana, Laura; Padhiar, Amie; Naessens, Dominik; Diels, Joris; van Sanden, Suzy; Pacou, Maud.

Afiliación

Welty M; Amaris, Health Economics and Market Access, Toronto, Canada.
Mesana L; Amaris, Health Economics and Market Access, Jersey City, NJ, USA.
Padhiar A; Amaris, Health Economics and Market Access, London, UK.
Naessens D; Janssen Pharmaceutica NV, Beerse, Belgium.
Diels J; Janssen Pharmaceutica NV, Beerse, Belgium.
van Sanden S; Janssen Pharmaceutica NV, Beerse, Belgium.
Pacou M; Amaris, Health Economics and Market Access, Paris, France.

Curr Med Res Opin ; 36(4): 595-606, 2020 04.

Article en En | MEDLINE | ID: mdl-31960724

Asunto(s)

Colitis Ulcerosa/tratamiento farmacológico; Metaanálisis en Red; Factor de Necrosis Tumoral alfa/antagonistas & inhibidores; Ustekinumab/uso terapéutico; Teorema de Bayes; Humanos

Palabras clave

Ulcerative colitis; biological therapies; comparative efficacy; network meta-analysis; ustekinumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Colitis Ulcerosa / Factor de Necrosis Tumoral alfa / Ustekinumab / Metaanálisis en Red Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Curr Med Res Opin Año: 2020 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google